Skip to content

Author

F. Borges

We have 3 of 65 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Dual inhibitors of SARS-CoV-2 Nsp13 helicase functions with broad anti-hCoV activity and combination effects with approved antivirals.

The SARS-CoV-2 non-structural protein 13 (nsp13) is a highly conserved helicase essential for viral replication and immune evasion. Its conservation across coronaviruses makes it an attractive target for the development of broad-spectrum antiviral agents. Hence, we rationally designed and synthesised 42 novel 2-iminoth...

Erica Sanna, A. Corona, S. Distinto et al. · 0 citations
Open access Sep 2026

Discovery of Novel Ligands for the Treatment of Cryptococcus neoformans Infection

Fungal pathogens are an escalating global public health concern, particularly in the context of invasive and opportunistic infections. Cryptococcosis, primarily caused by Cryptococcus neoformans var. grubii, can affect multiple organs and often leads to life‐threatening meningitis in immunocompromised individuals. Give...

T. Rocha, Catarina Alves, Carla Lima et al. · 0 citations
Review Open access Aug 2026

Cysteine-targeting covalent inhibition: Recent trends and emerging strategies.

Design and chemistry principles of cysteine-targeting covalent inhibitors are addressed, with a focus on the diversity of electrophilic warheads currently used or under research, and established motifs are discussed alongside newfound warheads.

Mariana Castelôa, F. Borges, S. Benfeito et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.